# IMPAACT Leadership Group

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2024 · $14,463,085

## Abstract

The over-arching goal of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Network is to identify safe, acceptable, feasible and effective interventions that will lead to the end of the HIV
epidemic among infants, children, adolescents and pregnant and postpartum women worldwide. To achieve
this goal, the Network will evaluate new and longer-lasting treatments for both HIV and tuberculosis (TB) and
strategies for antiretroviral treatment (ART)-free remission and address the complications, co-morbidities, and
co-infections affecting these populations. The Network’s scientific specific aims are 1) to advance antiretroviral
treatment of pregnant and postpartum women with HIV, aiming to optimize maternal and child health
outcomes, and to accelerate the evaluation (pharmacokinetics (PK), safety, antiviral efficacy), licensure and
optimal use of potent and durable antiretrovirals for pregnant women, infants, children and adolescents with
HIV; 2) to evaluate the potential for ART-free remission through therapeutic interventions aimed at prevention,
clearance and post-treatment control of HIV reservoirs in infants, children, and adolescents with HIV; 3) to
evaluate novel approaches for TB prevention, diagnosis and treatment in pregnant and postpartum women and
infants, children and adolescents with and without HIV that will lead to optimal dosing, regimens, licensing and
improved treatment outcomes; and 4) to determine optimal and feasible methods for the prevention and
management of complications and co-infections of HIV infection and its treatment in infants, children,
adolescents and pregnant and postpartum women. The Network will identify and evaluate the most promising
and relevant agents and interventions for our populations of interest, based on favorable safety, acceptability,
durability and efficacy profiles among non-pregnant adults, for evaluation in phase I-IV clinical research
studies, following the sequential drug development model. Strategy studies will also be pursued for targeted
interventions and populations. The Network will employ innovative study designs when appropriate to enhance
efficiency while maintaining scientific rigor. State-of-the-art socio-behavioral and pharmacometric methods will
be integrated into IMPAACT studies to ensure appropriate assessment of factors that may influence outcomes
of interest. When appropriate, the Network will pursue early phase evaluation of agents/interventions in infants,
children, adolescents and pregnant women in parallel with studies being conducted by other researchers with
the same agents/interventions in non-pregnant adults. IMPAACT studies are expected to be conducted at
experienced clinical research sites in Africa, Asia, and the Americas. The Network’s research will be developed
and conducted with community input at every level and in collaboration with other clinical trials networks,
research groups, pharmaceutical industry and other partners. Studies with t...

## Key facts

- **NIH application ID:** 10745702
- **Project number:** 5UM1AI068632-18
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Sharon A Nachman
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $14,463,085
- **Award type:** 5
- **Project period:** 2006-06-29 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10745702

## Citation

> US National Institutes of Health, RePORTER application 10745702, IMPAACT Leadership Group (5UM1AI068632-18). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10745702. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*